		Technical Data
C9100-15F	Cytomegalovirus, 65kD Late Antigen (CMV pp65, 65kD Matrix Phosphoprotein, 65kD Phosphoprotein, HCMV, Human Herpesvirus 5, HHV-5, HHV5, HHV5wtgp077, PP65, Tegument Protein pp65, Tegument Protein UL83, UL83)

Description:
Cytomegalovirus (CMV) is an opportunistic pathogen that infects lung, kidney, gut and other organs in immunologically immature individuals or in immunosuppressed patients. An active CMV infection time course in immunosuppressed individuals is characterized by a period of several weeks of pp65 antigenemia that corre- lates with viral replication, before the onset of clinical symptoms. This pool of 2 antibodies will detect the pp65 antigen in tissues and cytospins.

Applications:
Suitable for use in Immunofluorescence, Western Blot and Immunohistochemistry. Other applications not tested.

Recommended Dilution:
Immunofluorescence: 1:10-1:20
Western Blot: 1:1000
Immunohistochemistry: 1:200 for 1 hr. at RT
Optimal dilutions to be determined by the researcher.

Positive Control:
Western Blot: CMV-infected cells.
Immunohistochemistry: Cytomegalovirus-infected lung (nuclear and cytoplasmic staining pattern)

Storage and Stability:
Lyophilized powder may be stored at -20°C. Stable for 12 months at -20°C. Reconstitute with sterile ddH2O. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Reconstituted product is stable for 12 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Type	Isotype	Clone	Grade
Mab	IgG1,k	2/6	Supernatant

Size		Storage	Shipping	Source	Host
1ml		-20°C	Blue Ice		Mouse

Concentration:

Not determined

Immunogen:

Recombinant protein representing a portion at the C-terminal end of the cytomegalovirus pp65.

Purity:

Supernatant

Form

Supplied as a lyophilized powder in PBS, 1% BSA, 15mM sodium azide. Reconstitute with 1ml dH2O.

Specificity:

Recognizes Cytomegalovirus.

Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.

1.Gerna G, Percivalle E, Revello M G, et al.. Correlation of quantitative human cytomegalovirus pp65-, p72- and p150-antigenemia, viremia and circulating endothelial giant cells with clinical symptoms and antiviral treatment in immunocompromised patients. Clinical and Diagnostic Virology. 1:47-59 (1993). 2.Gerna G, Revello M G, Percivalle E, et al.. Comparison of different immunostaining techniques and monoclonal antibodies to the lower matrix phos- phoprotein (pp65) for optimal quantitation of human cytomegalovirus antigenemia. Journal of Clinical Microbiology. 30:1232-1237 (1992). 3.The T H, van der Ploeg M, van den Berg A P, et al.. Direct detection of cytomegalovirus in peripheral blood leukocytes - a review of the antigenemia assay and polymerase chain reaction. Transplantation. 54(2):193-198 (1992). 4.Gerna G, Zipeto D, Parea M, et al.. Monitoring of human cytomegalovirus infections and ganciclovir treatment in heart transplant recipients by determination of viremia, antigenemia and DNAemia. The Journal of Infectious Diseases. 164:488-498 (1991). 5.van den Berg A P, van der Bij W, van Son W J, et al.. Cytomegalovirus antigenemia as a useful marker of symptomatic cytomegalovirus infection after renal transplantation - a report of 130 consecutive patients. Transplantation. 48(6):991-995 (1989).